Elevance Health, Inc. $ELV Shares Sold by IPG Investment Advisors LLC

IPG Investment Advisors LLC reduced its position in Elevance Health, Inc. (NYSE:ELV) by 65.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,212 shares of the company’s stock after selling 4,143 shares during the period. IPG Investment Advisors LLC’s holdings in Elevance Health were worth $775,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Sound View Wealth Advisors Group LLC lifted its stake in shares of Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after purchasing an additional 29 shares in the last quarter. Fulton Breakefield Broenniman LLC lifted its position in Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after acquiring an additional 29 shares in the last quarter. Perigon Wealth Management LLC lifted its position in Elevance Health by 2.2% during the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after acquiring an additional 29 shares in the last quarter. Savvy Advisors Inc. lifted its position in Elevance Health by 3.2% during the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock worth $343,000 after acquiring an additional 30 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its position in Elevance Health by 6.1% during the 4th quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock worth $195,000 after acquiring an additional 32 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ELV has been the topic of several recent research reports. The Goldman Sachs Group boosted their price target on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Barclays boosted their price target on Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and boosted their price target for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $405.00 to $435.00 in a research report on Wednesday, April 29th. Finally, Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $403.11.

Elevance Health Stock Performance

Shares of ELV opened at $391.00 on Thursday. The business’s 50 day moving average is $339.83 and its two-hundred day moving average is $337.98. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $408.00. The firm has a market cap of $84.91 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 2.20 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same period in the prior year, the company posted $11.97 EPS. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts forecast that Elevance Health, Inc. will post 26.91 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.